Our Scientific Founder Professor Annibale Puca is a leading expert on longevity. For three decades he has been studying long living individuals. His discovery of a key longevity associated protein has paved the way for a new class of medicines.
Learn how we develop medicines based on the longevity associated protein LAV-BPIFB4 found in long living individuals.
In studies covering more than 5,000 people, Professor Puca was the first to discover the longevity associated protein LAV-BPIFB4 that works as the 'caretaker' of the human cells in long living individuals.
As any good caretaker LAV-BPIFB4 looks out for and repairs age-related damages in the cells. Its proactive multifactorial repair keep damages from accumulating and causing permanent loss of function.
RX-1 is the first long-acting non-invasive therapy with a strong preclinical proof-of-concept in Huntington's Disease.
Our ambition is to develop RX-1 as a treatment for Huntington’s Diseases, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.
Our scientists have extensively researched the therapeutic and mechanistic characteristics of LAV-BPIFB4 over last decades. Here are some recent publications:
We are a team of leading scientists, drug development experts, and industry leaders from Denmark, Italy, England, and Germany. We work collaboratively from our business operations in Denmark and our research operations in Italy.
Andreas Christensen, Co-founder & CEO
Roxiant relies on financing from investors to accelerate our drug development program. We invite investors to contact our CEO Andreas Christensen (asc@roxiant.com) if you are interested in:
1. Receiving our investor presentation
2. Scheduling an introductory meeting
3. Signing-up for our investor newsletters
Roxiant’s novel therapeutic platform has demonstrated strong in vivo proof-of-concept in multiple diseases with complex pathologies. It may exert therapeutic effects in areas with significant unmet medical needs:
Supported by strong patent protection with late expiry, our out-licensed partnership program is aimed at accelerating the development of novel drug candidates for patients with unmet medical needs.
We invite potential drug development and licensing partners to contact our CEO Andreas Christensen (asc@roxiant.com).
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.